Mr. Aldrich is a Co-Founder of OvaScience and is Chairman of the company’s Board of Directors. Mr. Aldrich is also a Founder and Partner of Longwood Fund, which founds and invests in biotechnology companies. Mr. Aldrich has co-founded and helped to build several successful biotech companies including Sirtris Pharmaceuticals (acquired by GlaxoSmithKline), Concert Pharmaceuticals, Alnara Pharmaceuticals (acquired by Eli Lilly in 2010) and Verastem. Prior to co-founding Longwood, he was General Partner of RA Capital, a biotechnology investment fund he founded in 2001. Mr. Aldrich was a founding employee of Vertex Pharmaceuticals, where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to joining Vertex, Mr. Aldrich held several management positions at Biogen, Inc. Mr. Aldrich serves on the Board of the Massachusetts Eye & Ear Infirmary.
Mr. Aldrich received his undergraduate degree from Boston College, and an M.B.A. from the Amos Tuck School at Dartmouth College.
Jeffrey D. Capello is the former Executive Vice President and Chief Financial Officer of Boston Scientific. There he was directly responsible for the worldwide management of Boston Scientific's Finance Information Systems, Business Development and Corporate Strategy functions. Prior to joining Boston Scientific, he was the Senior Vice President and Chief Financial Officer with responsibilities for Business Development at PerkinElmer, Inc. from 2006 to 2008. Prior to that, he served as PerkinElmer's Vice President of Finance, Corporate Controller and Treasurer from 2002 to 2006 and as Vice President, Finance, Corporate Controller, Chief Accounting Officer and Treasurer from 2001 to 2005. From 1991 to June 2001, he held various positions including that of partner from 1997 to 2001, at PricewaterhouseCoopers LLP, a public accounting firm, initially in the United States and later in the Netherlands. Mr. Capello was a member of the board of directors of Sirtris Pharmaceuticals, Inc. (acquired by GlaxoSmithKline) and served on its Audit Committee as both a member and its chair.
Mr. Capello holds a B.S. degree in business administration from the University of Vermont and an M.B.A. degree from the Harvard Business School. Mr. Capello is also a certified public accountant.
Dr. Dipp is the founding Chief Executive Officer of OvaScience and serves on the Board of Directors. Dr. Dipp is also a Founder and Partner of Longwood Fund, which founds and invests in healthcare companies such as Alnara (acquired by Eli Lilly) and Verastem. Previously, Dr. Dipp was the Senior Vice President and Head of the CEEDD at GlaxoSmithKline. Prior, she was Vice President of Corporate Development at Sirtris, where she led the successful acquisition of Sirtris by GSK for $720 million. Before joining Sirtris as a founding employee, she worked in healthcare private equity at The Wellcome Trust, London. Dr. Dipp serves on the Biotechnology Industry Organization’s (BIO) Emerging Companies Governing Board, the Beth Israel Deaconess Medical Center Board of Trustees, the Boston Symphony Orchestra Board of Overseers, and the MassBio Advisory Board.
Dr. Dipp holds an M.D. and a Ph.D. from the University of Oxford.
Ms. Fisher serves on the Board of Directors of OvaScience and brings more than 25 years of experience in the pharmaceutical and biotechnology industries. Ms. Fisher currently serves as Chief Executive Officer and Director at Colorescience, a former division of SkinMedica, Inc., where she served as Chief Executive Officer from 2008 until 2012, when she led the successful sale of the company to Allergan, Inc. for $375 million. Prior to joining SkinMedica, Ms. Fisher was the Chief Operating Officer of Acorda Therapeutics, where she was responsible for the execution of the company?s restructuring, initial public offering and a $50 million acquisition that transitioned Acorda from a developmental platform to a commercial stage operation. Ms. Fisher has served as a Pharmaceutical Consultant for companies such as Acorda Therapeutics and Roche Diagnostics and specialized in commercialization strategy, resource and outsource planning, pricing strategy and tactics, distribution planning, managed care contracting and forecasting. Previously, she held the role of Vice President, Strategic Healthcare and Commercial Operations at Cephalon, Inc., and Manager, Communications at Immunex. She currently serves as a Board Member of the Neuroscience Nursing Foundation and is a Member of the Women?s Dermatological Society and the Dermatology Foundation Leader?s Society. Additionally, Ms. Fisher co-founded Ann Olsen Endowment, a cancer patient advocacy group, in 1987.
Mr. Kozin has nearly 30 years of experience in corporate and business unit strategy consulting, merger and acquisition advisory services, and value management both domestically and internationally. Mr. Kozin served as president of the North American practice of L.E.K., a global strategy consulting firm, for 15 years and has been a Senior Advisor to L.E.K. since July 2011. He currently serves as a member of the Board of Directors of UFP Technologies, Inc., DYAX Corp., Endocyte, Inc., and three privately-held companies. He also serves on the strategic advisory board for Healthcare Royalty Partners, a global healthcare investment firm. Mr. Kozin holds a B.A., with distinction, in economics from Duke University and an M.B.A., with distinction, from The Wharton School, University of Pennsylvania.
Mr. Kraus serves on the Board of Directors of OvaScience and is a partner of Bessemer Venture Partners (BVP) in the company’s Cambridge, Mass. Office. He has worked with BVP since 2004 and focuses on the healthcare sector. Mr. Kraus has been actively involved in BVP’s investments in Sirtris Pharmaceuticals (acquired by GlaxoSmithKline); Affymax; AVEO Pharmaceuticals; Alnara, acquired by Eli Lilly; Transave; and Restore Medical, acquired by Medtronic. He currently sits on the boards of Verastem, Stromedix and On-Q-ity and is actively involved in BVP's investments in Acceleron, Proteon, Oxagen and Cerulean. Prior to joining Bessemer, Mr. Kraus was a Director at the Ironwood Equity Fund, a growth-stage, private-equity firm, and a management consultant at Bain & Co. In 2002, he served as speechwriter and Operations Director for the Democratic nominee for Governor of Massachusetts.
Mr. Kraus graduated summa cum laude with a B.A. from Yale University and earned his M.B.A. from Harvard, where he was a Baker Scholar. He serves on the boards of the New England Venture Capital Association (NEVCA) and Interise, a non-profit focused on small-business job creation and entrepreneurship.
Thomas Malley has served on our board of directors since October 2012. He has been President of Mossrock Capital, a private investment firm in Denver, Colorado, since 2007. From 1991 until 2007 Mr. Malley worked at Janus Mutual Funds. From 1999–2007, he started and served as the portfolio manager of the Janus Global Life Sciences Fund, as well as being Vice President in charge of the Janus Healthcare team. From 1991-1998 he served as an equity analyst for Janus covering healthcare and biotechnology, telecommunications, gaming and lodging, and housing stocks. Mr. Malley serves on the board of directors of Synageva Biopharma and Puma Biotechnology, both of which are publicly traded biotechnology firms. In the past, he served on the board of Cougar Biotechnology from 2007–2009, prior to its acquisition by Johnson and Johnson.
Mr. Malley earned his B.S. degree in Biology from Stanford University in 1991.
Mr. Stock serves on the Board of Directors of OvaScience and is a member of its Audit and Compensation Committees. Harald has been President & Chief Executive Officer of Malmö, Sweden based ArjoHuntleigh AB, a leading medical device company offering innovative solutions in acute and long-term care, and Executive Vice President of Getinge Group’s (OMX: GETI B) Extended Care Business Area since January 1, 2014. Before joining ArjoHuntleigh and Getinge Group he was the Chief Executive Officer of Grünenthal, a privately held, international research-based pharmaceutical company, headquartered in Germany. Prior to joining Grünenthal in 2009, he was Chairman and Managing Director at DePuy, the Orthopedics Division of Johnson & Johnson. Previously, he held various positions of increasing responsibilities in local and global functions and corporate divisions of the Roche Group until 2005, when he was appointed Senior Vice President of the Global Near Patient Testing business based in Graz, Austria.
Mr. Stock served as a Board Member at the European Federation of Pharmaceutical Industries and Associations (efpia) and is a board member at immatics biotechnologies GmbH. He also previously served as Vice-Chairman of the Supervisory Board of PAION AG, was Board Observer of ConforMIS, Inc. and represented Johnson & Johnson on the Board of BVMed, the German Medical Technology Industry Association.
Harald holds a PhD. in Inorganic Chemistry from Ruprecht-Karls-University of Heidelberg, Germany.
Dr. Westphal is a Partner of Longwood Fund, which founds and invests in medical companies, and is Chairman and CEO of Verastem. He was founder and CEO of Sirtris Pharmaceuticals (acquired by GlaxoSmithKline), which he took public and led as Chief Executive Officer until 2010. Dr. Westphal cofounded Alnara Pharmaceuticals (acquired by Eli Lilly in 2010), and was co-founder/CEO of Alnylam Pharmaceuticals and Momenta Pharmaceuticals. Dr. Westphal serves on the board of directors of Ovascience (which he cofounded), and serves on the Board of Fellows of Harvard Medical School, and the Board of Overseers of the Boston Symphony Orchestra.
Dr. Westphal earned his M.D. from Harvard Medical School and Ph.D. in genetics from Harvard University and he graduated with a B.A. summa cum laude and Phi Beta Kappa from Columbia University.